GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
MWN-AI** Summary
GeneDx, a leader in rare disease diagnostics, has announced a partnership with Zevra Therapeutics to launch a genetic testing program aimed at enhancing access to testing for Niemann-Pick Disease Type C (NPC). This initiative is particularly noteworthy as NPC is a rare and often underdiagnosed condition that leads to severe neurological and organ complications due to lipid transport disorders caused by mutations in the NPC1 and NPC2 genes.
The program will expand access to GeneDx's ExomeDx™ test, enabling clinicians to confirm or rule out NPC diagnoses more swiftly. Eligible patients in the U.S. will receive the testing at no charge, and results can be expected in as little as three weeks. This collaboration underscores the significance of timely genetic diagnosis, especially as new treatment options for NPC emerge.
Zevra Therapeutics will provide financial backing for the program, emphasizing its commitment to improving patient outcomes through enhanced diagnostic capabilities. The data collected will also contribute to GeneDx Infinity™, the world's largest rare disease genomic dataset, which aims to enrich understanding of NPC biology and expedite the journey from diagnosis to treatment.
Both companies recognize the emotional and clinical toll of delayed diagnosis for NPC patients and their families. Joshua Schafer from Zevra highlighted the strategic importance of this partnership in streamlining the diagnostic process to alleviate uncertainty and facilitate quicker access to appropriate therapies.
GeneDx’s Chief Business Officer, Lisa Gurry, remarked on the critical role of genomic insights in transforming patient care and enabling informed clinical decision-making. This collaboration not only aims to aid individual patients but also holds the promise of advancing the broader field of genomic precision medicine.
MWN-AI** Analysis
GeneDx's recent partnership with Zevra Therapeutics to launch a genetic testing program aimed at Niemann-Pick Disease Type C (NPC) represents a formidable opportunity within the healthcare market, particularly in the rapidly expanding genomic medicine sector. This program, which provides the ExomeDx™ test at no charge to eligible U.S. patients, is noteworthy for several reasons that investors should take into account.
First, the innovation showcased by GeneDx underscores its leadership in rare diseases and genomics, utilizing the comprehensive GeneDx Infinity™ dataset to fuel better diagnostic outcomes. The utilization of advanced genomic data positions GeneDx favorably against competitors, potentially translating to increased market share and revenue growth. The swift turnaround for test results (approximately three weeks) enhances appeal to both clinicians and patients—timeliness is critical in managing progressive diseases like NPC.
Moreover, as healthcare systems pivot toward precision medicine, partnerships, like the one with Zevra, will likely enhance distribution networks and expand access to genetic testing. With NPC diagnosed frequently late due to symptom variability, this collaborative program could fundamentally alter patient outcomes, further validating GeneDx’s value proposition.
From a financial perspective, investors should consider the implications of increasing public and institutional attention on rare disease treatment advancements. As Zevra commits to funding this initiative, there is potential for enhanced collaboration in future therapeutic development, providing GeneDx with additional revenue streams.
Nonetheless, investors should remain cautious of inherent risks, including regulatory changes or market competition that could affect GeneDx’s strategic objectives. As such, a balanced assessment of GeneDx’s innovative capabilities against market pressures is essential for informed investment decisions. Overall, this program signifies a pivotal development in the genomic landscape, positioning GeneDx for potential growth and long-term success.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diagnoses faster and guide clinical decision-making. De-identified data from the program will be added to GeneDx Infinity™, the largest and most comprehensive rare disease dataset, to help drive faster diagnoses of NPC to help patients and providers make informed treatment decisions.
NPC is a rare, inherited, and often underdiagnosed condition that can progress relentlessly while families search for answers. Through this program, eligible patients in the United States will have access to genomic testing via GeneDx to help confirm or rule out a diagnosis of NPC. Providing data to support an accurate diagnosis is a critical step in guiding patient management and identifying individuals who may benefit from available therapies. The program builds on Zevra’s leadership in NPC underscoring the growing importance of timely and accurate genetic diagnosis as new treatment options emerge.
“When a disease is progressive and treatable, every day matters. Through our partnership with Zevra we are removing barriers to high-quality exome sequencing so clinicians can reach answers faster, confirm diagnoses with precision, and identify patients earlier,” said Lisa Gurry, Chief Business Officer at GeneDx. “Our partnership programs are fueled by the GeneDx Infinity™ dataset – the world’s largest rare-disease genomic dataset – enabling biopharma partners to better understand disease biology, and accelerate the patient journey from diagnosis to treatment. This is how we translate genomic insight into transformative, real-world impact for patients.”
NPC is caused by mutations in the NPC1 and NPC2 genes that impair the body’s ability to transport cholesterol and other lipids. This disruption leads to abnormal lipid buildup in the brain, liver, spleen, and lungs, resulting in progressive neurodegeneration, organ involvement, and potentially fatal outcomes. Symptoms can emerge in childhood or adulthood, and diagnosis is often delayed due to wide clinical variability and overlap with other neurological and metabolic conditions.
“NPC is a devastating disease that is frequently underrecognized, often leading to delays in diagnosis and treatment,” said Joshua Schafer, Zevra’s Chief Commercial Officer. “This strategic partnership with GeneDx will enhance access to genetic testing and supports physicians in identifying NPC patients earlier, enabling more timely and informed clinical decision-making. By accelerating the diagnostic process, we hope to reduce uncertainty for families and ensure patients can access appropriate treatment as quickly as possible.”
Through the program, GeneDx is slated to offer testing to U.S.-based clinicians caring for patients with known or suspected NPC who meet eligibility criteria. Patients will then be eligible to receive GeneDx's ExomeDx test at no charge and results will be provided to clinicians and their patients in as little as three weeks. Zevra Therapeutics will provide financial support for the program as part of its commitment to advancing diagnosis and care in NPC.
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn , Facebook , and Instagram .
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans and strategic partnerships, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260310450068/en/
Investor Relations Contact:
Investors@GeneDx.com
Media Contact:
Press@GeneDx.com
FAQ**
How does the partnership between GeneDx Holdings Corp. (Nasdaq: WGS) and Zevra Therapeutics, Inc. (Nasdaq: ZVRA) enhance diagnostic capabilities for Niemann-Pick disease type C (NPC) and what potential impact might this have on patient outcomes?
What specific eligibility criteria must patients meet to access GeneDx’s ExomeDx test at no charge under the NPC Sponsored Genetic Testing Program, and how is GeneDx Holdings Corp. WGS ensuring equitable access to this test?
In what ways might the de-identified data collected through the NPC testing program contribute to advancing rare disease diagnosis and treatment options, as stated by GeneDx Holdings Corp. WGS?
Considering the emerging treatment options for NPC, how does GeneDx’s commitment to genomic sequencing align with the broader goals of reducing delays in diagnosis and improving patient care, and what role does Zevra Therapeutics play in this initiative?
**MWN-AI FAQ is based on asking OpenAI questions about GeneDx Holdings Corp. (NASDAQ: WGS).
NASDAQ: WGS
WGS Trading
-2.5% G/L:
$76.635 Last:
221,882 Volume:
$78.02 Open:
